Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab Plus Lenalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Newly Diagnosed Multiple Myeloma
NCT05145400Phase 2Recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Feb 2022
- Primary completion
- May 2033
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in multiple myeloma (MM), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Overall Response Rate up to 60 months. Started Feb 2022; status: recruiting.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05145400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145400.